Back to search results

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

This study is for lung transplant recipients aged 18 to 99 who need a lung biopsy. Researchers are comparing two ways to collect lung tissue: using standard biopsy forceps (Olympus disposable EndoJaw) or a flexible cryoprobe (Erbe Elektromedizin GmbH). The goal is to see which method provides better quality tissue samples to help doctors diagnose rejection more accurately. They want to know if one method gives more useful tissue, if pathologists are more confident in their findings with one method, and which method takes less time. This study aims to improve how doctors detect rejection in transplanted lungs.

Study design
This is a randomized clinical trial comparing two biopsy methods in about 100 participants.
What's involved
You would undergo a bronchoscopy with transbronchial biopsy, where tissue samples are collected using both methods.
Compensation
Not stated in the trial record.
Follow-up
Tissue sample quality and diagnostic yield will be measured at baseline, which is the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06824402

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

Recruiting
NAAges 18–99InterventionalHealth services
Mayo Clinic
~100 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Forceps BiopsyCryoprobe Biopsy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quality and diagnostic yield of tissue samples
Measured over Baseline

Conditions

Lung Transplant Rejection

Explore related trials

Lung TransplantationLung transplant rejection

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • John Joerns · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

John Joerns, MD
[email protected]
507-284-6616
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male and female lung transplant recipients age \>18 at the time of informed consent
Patients clinically meet indication for post-transplant lung biopsy or planned routine surveillance and have been scheduled for bronchoscopy with transbronchial biopsy.
Be willing and able to sign the informed consent.

Exclusion

Patients with known bleeding diathesis
Platelet count \<50,000 per μL within 14 days of the biopsy procedure
Current use of systemic anticoagulation or antiplatelet therapy without the ability to hold therapy for the recommended amount of time prior to an invasive procedure (aspirin monotherapy is acceptable)
Inability or unwillingness to give informed consent or study procedures
Pregnant or nursing females, or females who intend to become pregnant
Females of child-bearing potential who decline a pregnancy test prior to enrollment
If an investigator does not feel that this study is in the subject's best interest or would be a good fit for the study.
International Normalized Ratio (INR) \>1.5
Do Not Resuscitate (DNR) status
Do Not Intubate (DNI) status
Single lung transplant recipients

What this trial measures

  • Quality and diagnostic yield of tissue samplesBaseline

    Histological accessibility grade is determined by the pathologist according to the Lung Allograft Standard Histological Analysis (LASHA) scale and the 2007 Revision of the 1996 working formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection, published by the ISHLT.